Reduced Oxidative Stress in STEMI Patients Treated by Primary Percutaneous Coronary Intervention and with Antioxidant Therapy: A Systematic Review

Keyphrases

• Allopurinol 42%
• Antioxidant Therapy 100%
• Atorvastatin 42%
• Cardiac Adverse Events 14%
• Cardiac Function 28%
• Clinical Benefit 14%
• Clinical Outcomes 57%
• Clinical Trials 14%
• Complex Link 14%
• Coronary Intervention 14%
• Coronary Perfusion 14%
• Deferoxamine 28%
• Edaravone 42%
• Embase 14%
• Functional Outcome 14%
• Glucose-insulin-potassium 14%
• Ischemia-reperfusion Injury 42%
• Methodological Quality 14%
• Myocardial Infarction Patients 100%
• Myocardial Injury 28%
• Myocardial Ischemia-reperfusion Injury 14%
• N-acetylcysteine 28%
• Nicorandil 42%
• Oxidative Stress 100%
• Oxidative Stress Damage 14%
• Primary Percutaneous Coronary Intervention 100%
• PubMed 14%
• Randomized Clinical Trial 14%
• Reperfusion 28%
• ST-elevation Myocardial Infarction (STEMI) 100%
• Stress Function 14%
• Vitamin C 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Acetylcysteine 66%
• Adverse Event 33%
• Allopurinol 100%
• Antioxidant 100%
• Atorvastatin 100%
• Clinical Trial 33%
• Deferoxamine 66%
• Edaravone 100%
• Heart Muscle Injury 66%
• Isotopes of Potassium 33%
• Myocardial Ischemia Reperfusion Injury 33%
• Nicorandil 100%
• Randomized Clinical Trial 33%
• Reperfusion Injury 100%
• ST Segment Elevation Myocardial Infarction 100%